TY - JOUR
T1 - Carotid plaque, a subclinical precursor of vascular events
T2 - The Northern Manhattan Study
AU - Rundek, T.
AU - Arif, H.
AU - Boden-Albala, B.
AU - Elkind, M. S.
AU - Paik, M. C.
AU - Sacco, R. L.
N1 - Funding Information:
Supported in part by the Gilbert Baum Memorial Grant and the Goddess Fund for Stroke Research in Women (TR) and by grants from the National Institute of Neurological Disorders and Stroke, R01 29993 (TR, RLS), K23 NS42912 (MSVE), AHA (Kathleen Scott Research Fellowship, MSVE), and the General Clinical Research Center (2 M01 RR00645).
PY - 2008/4
Y1 - 2008/4
N2 - BACKGROUND: Carotid atherosclerosis is a known biomarker associated with future vascular disease. The risk associated with small, nonstenotic carotid plaques is less clear. The objective of this study was to examine the association between maximum carotid plaque thickness and risk of vascular events in an urban multiethnic cohort. METHODS: As part of the population-based Northern Manhattan Study, carotid plaque was analyzed among 2,189 subjects. Maximum carotid plaque thickness was evaluated at the cutoff level of 1.9 mm, a prespecified value of the 75th percentile of the plaque thickness distribution. The primary outcome measure was combined vascular events (ischemic stroke, myocardial infarction, or vascular death). RESULTS: Carotid plaque was present in 1,263 (58%) subjects. After a mean follow-up of 6.9 years, vascular events occurred among 319 subjects; 121 had fatal or nonfatal ischemic stroke, 118 had fatal or nonfatal myocardial infarction, and 166 died of vascular causes. Subjects with maximum carotid plaque thickness greater than 1.9 mm had a 2.8-fold increased risk of combined vascular events in comparison to the subjects without carotid plaque (hazard ratio, 2.80; 95% CI, 2.04-3.84). In fully adjusted models, this association was significant only among Hispanics. Approximately 44% of the low-risk individuals by Framingham risk score had a 10-year vascular risk of 18.3% if having carotid plaque. CONCLUSIONS: Maximum carotid plaque thickness is a simple and noninvasive marker of subclinical atherosclerosis associated with increased risk of vascular outcomes in a multiethnic cohort. Maximum carotid plaque thickness may be a simple and nonexpensive tool to assist with vascular risk stratification in preventive strategies and a surrogate endpoint in clinical trials.
AB - BACKGROUND: Carotid atherosclerosis is a known biomarker associated with future vascular disease. The risk associated with small, nonstenotic carotid plaques is less clear. The objective of this study was to examine the association between maximum carotid plaque thickness and risk of vascular events in an urban multiethnic cohort. METHODS: As part of the population-based Northern Manhattan Study, carotid plaque was analyzed among 2,189 subjects. Maximum carotid plaque thickness was evaluated at the cutoff level of 1.9 mm, a prespecified value of the 75th percentile of the plaque thickness distribution. The primary outcome measure was combined vascular events (ischemic stroke, myocardial infarction, or vascular death). RESULTS: Carotid plaque was present in 1,263 (58%) subjects. After a mean follow-up of 6.9 years, vascular events occurred among 319 subjects; 121 had fatal or nonfatal ischemic stroke, 118 had fatal or nonfatal myocardial infarction, and 166 died of vascular causes. Subjects with maximum carotid plaque thickness greater than 1.9 mm had a 2.8-fold increased risk of combined vascular events in comparison to the subjects without carotid plaque (hazard ratio, 2.80; 95% CI, 2.04-3.84). In fully adjusted models, this association was significant only among Hispanics. Approximately 44% of the low-risk individuals by Framingham risk score had a 10-year vascular risk of 18.3% if having carotid plaque. CONCLUSIONS: Maximum carotid plaque thickness is a simple and noninvasive marker of subclinical atherosclerosis associated with increased risk of vascular outcomes in a multiethnic cohort. Maximum carotid plaque thickness may be a simple and nonexpensive tool to assist with vascular risk stratification in preventive strategies and a surrogate endpoint in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=41649115576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41649115576&partnerID=8YFLogxK
U2 - 10.1212/01.wnl.0000303969.63165.34
DO - 10.1212/01.wnl.0000303969.63165.34
M3 - Article
C2 - 18354078
AN - SCOPUS:41649115576
SN - 0028-3878
VL - 70
SP - 1200
EP - 1207
JO - Neurology
JF - Neurology
IS - 14
ER -